- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1750 |
Product Name |
ADT1750-Human Anti-CD3xBCMA Bispecific Antibody |
Isotype |
Human IgG4-lambda1mutation |
Clonity |
Monoclonal |
|
Alternate Names Human Anti-CD3 mAb, Anti-CD3 Monoclonal Antibody, CD3 recombinant antibody, Anti-CD3 Bispecific Antibody, Human Anti-BCMA mAb, BCMA recombinant antibody, Anti-BCMA Monoclonal Antibody, Anti-BCMA Bispecific Antibody |
|
Official Symbol |
CD3xBCMA |
Target 1 |
CD3 |
Gene ID 1 |
916 |
Target 2 |
BCMA |
Gene ID 2 |
608 |
Species |
Human |
Drug Name |
Teclistamab |
Endotoxin |
<1EU/mg. Determined by the LAL method. |
Sterility |
0.2 μM filtered. |
Expression Host |
CHO Cells |
CAS Number |
2119595-80-9 |
Chemical Formula |
C6383H9847N1695O2003S40 |
Molecular Weight |
146 KDa |
Product Description |
Teclistamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T cell engager used to treat relapsed and refractory multiple myeloma in adults as monotherapy. |
Mechanism of Action |
Teclistamab is a bispecific T cell engaging antibody that targets the CD3 receptor, which is expressed on the surface of T cells, and BCMA, which is expressed on malignant cells. Due to its dual binding sites, teclistamab is able to draw CD3+ T cells in close proximity to BCMA+ cells, resulting in T cell activation and T cell-mediated cytotoxicity, which is mediated by secreted perforin and various granzymes stored in the secretory vesicles of cytotoxic T cells. |
Size |
1mg,5mg,50mg,100mg |
Research Area |
Cancer |
Application |
FuncS |
Purity |
>90% |
Concentration |
Batch dependent |
Buffer |
Supplied in PBS, pH 7.4,Contains no stabilizers or preservatives |
Recommended Dilution Buffer |
ABDB-1002 or PBS, pH 7.4, Contains no stabilizers or preservatives. |
Storage |
2 weeks, 2-8℃ under sterile conditions after reconstitution. Avoid repeated freeze-thaw. -80°C for one-year storage. |
Shipping Condition |
Shipped on ice packs. |
Protocol Information |
Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose-response or titration experiment. |
Note |
For Research Use Only! |
|
Reference 1. Pillarisetti K, Powers G, Luistro L, Babich A, Baldwin E, Li Y, Zhang X, Mendonca M, Majewski N, Nanjunda R, Chin D, Packman K, Elsayed Y, Attar R, Gaudet F: Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv. 2020 Sep 22;4(18):4538-4549. doi: 10.1182/bloodadvances.2020002393.
2. Wu L, Huang Y, Sienkiewicz J, Sun J, Guiang L, Li F, Yang L, Golubovskaya V: Bispecific BCMA-CD3 Antibodies Block Multiple Myeloma Tumor Growth. Cancers (Basel). 2022 May 20;14(10). pii: cancers14102518. doi: 10.3390/cancers14102518.
|
FAQ
-
+ -
What is BCMA?
B-cell maturation antigen (BCMA) is highly expressed in multiple myeloma cells, making it a key therapeutic target.
-
+ -
How can I obtain COA of the reagent that I received?
Please contact us via email info@alphalifetech.com for detailed information about the product.
-
+ -
How does CD3 engagement help?
By linking CD3 on T-cells to BCMA on myeloma cells, this antibody redirects T-cells to destroy cancer cells. -
+ -
What are the common structural formats of bispecific antibodies?
Formats include tandem scFv (BiTE), IgG-scFv fusion, CrossMab, knob-into-hole, and DVD-Ig. Each varies in size, stability, and functionality.